Financial reports
ARS
2023 FY
Annual report to shareholders
5 Apr 24
10-K
2023 FY
Annual report
5 Mar 24
10-Q
2023 Q3
Quarterly report
30 Oct 23
10-Q
2023 Q2
Quarterly report
3 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
ARS
2022 FY
Annual report to shareholders
7 Apr 23
10-K
2022 FY
Annual report
2 Mar 23
10-Q
2022 Q3
Quarterly report
3 Nov 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
10-Q
2022 Q1
Quarterly report
2 May 22
Current reports
8-K
Departure of Directors or Certain Officers
25 Mar 24
8-K
Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
5 Mar 24
8-K
Dyne Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock
5 Jan 24
8-K
Other Events
4 Jan 24
8-K
Dyne Therapeutics Announces Positive Initial Clinical Data from ACHIEVE Trial in DM1
3 Jan 24
8-K
Results of Operations and Financial Condition
30 Oct 23
8-K
Dyne Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
3 Aug 23
8-K
Departure of Directors or Certain Officers
25 May 23
8-K
Dyne Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
11 May 23
8-K
Regulation FD Disclosure
10 Mar 23
Registration and prospectus
S-3ASR
Automatic shelf registration
5 Mar 24
S-8
Registration of securities for employees
5 Mar 24
424B5
Prospectus supplement for primary offering
5 Jan 24
S-3MEF
Registration of additional securities for an S-3
4 Jan 24
424B5
Prospectus supplement for primary offering
3 Jan 24
S-8
Registration of securities for employees
2 Mar 23
S-8
Registration of securities for employees
10 Mar 22
S-3
Shelf registration
4 Nov 21
S-8
Registration of securities for employees
4 Mar 21
424B4
Prospectus supplement with pricing info
21 Jan 21
Proxies
DEFA14A
Additional proxy soliciting materials
5 Apr 24
DEF 14A
Definitive proxy
5 Apr 24
DEFA14A
Additional proxy soliciting materials
7 Apr 23
DEF 14A
Definitive proxy
7 Apr 23
DEFA14A
Additional proxy soliciting materials
22 Apr 22
DEF 14A
Definitive proxy
22 Apr 22
DEFA14A
Additional proxy soliciting materials
14 Apr 21
DEF 14A
Definitive proxy
14 Apr 21
Other
EFFECT
Notice of effectiveness
18 Nov 21
CORRESP
Correspondence with SEC
15 Nov 21
UPLOAD
Letter from SEC
10 Nov 21
EFFECT
Notice of effectiveness
21 Jan 21
CORRESP
Correspondence with SEC
19 Jan 21
CORRESP
Correspondence with SEC
19 Jan 21
UPLOAD
Letter from SEC
13 Jan 21
EFFECT
Notice of effectiveness
17 Sep 20
CERT
Certification of approval for exchange listing
16 Sep 20
CORRESP
Correspondence with SEC
14 Sep 20
Ownership
3/A
John Cox
4 Apr 24
4
Jonathan McNeill
4 Apr 24
SC 13G
RA CAPITAL MANAGEMENT, L.P.
4 Apr 24
144
Notice of proposed sale of securities
4 Apr 24
4
John Cox
27 Mar 24
3
John Cox
27 Mar 24
4
SUSANNA GATTI HIGH
13 Mar 24
4
Jonathan McNeill
13 Mar 24
4
Wildon Farwell
12 Mar 24
4
Richard William Scalzo
12 Mar 24